Screener
Climb Bio, Inc. CLYM Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Climb Bio, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
FAQ
- What is Climb Bio, Inc.'s return on equity?
- Climb Bio, Inc. (CLYM) reported return on equity of -30.9% in Q1 2026.
- How has Climb Bio, Inc.'s return on equity changed year-over-year?
- Climb Bio, Inc.'s return on equity increased by 50.2% year-over-year, from -62% to -30.9%.
- What is the long-term trend for Climb Bio, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Climb Bio, Inc.'s return on equity has grown at a 1.7% compound annual growth rate (CAGR), from -30.6% to -32.1%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Climb Bio, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude